Premier Biomedical, Inc.(OTCBB:BIEI), a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer’s Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Blood Sepsis and Viremia, and Cancer/Leukemia, today reported on recent successes in laboratory testing of its patent-pending technology at the University of Texas El Paso (UTEP).
According to William A. Hartman, President/CEO of Premier Biomedical, Inc., the successes in the laboratory centered around the test tube deaths of Cancer tissues through the Corporation’s patent-pending process of simply removing select molecular compounds. Mr. Hartman further commented, “This is HUGE NEWS in that Cancer tissues were destroyed within 24 hours without the addition of any other medications or procedures that might have potential side-effects on patients. This process could revolutionize medicine!” As a result, plans are being developed to start testing of this methodology on mice immediately.
In order to capitalize on these rapid developments, the Company has announced the establishment of five new Operating Divisions, each headed by a Vice President:
1) Cancer/Leukemia Division
2) Blood-Borne Pathologies Division
3) Cerebral Spinal Fluid (CSF) Pathologies Division
4) Alzheimer’s Disease/ALS/Traumatic Brain Injury (TBI) Division
5) Heart Attack/Stroke Division
The Company also announced the addition of two new members to the Board of Directors, namely John Borza and Richard Najarian. Biographies for these individuals as well as other Officers and BOD members can be found in the Company’s filings with the Securities and Exchange Commission, or on the Company’s web site at: www.premierbiomedicalinc.com.
